STereotactic Arrhythmia Radioablation and its implications for modern cardiac ElectroPhysiology: Results of an EHRA Survey

Background Stereotactic arrhythmia radioablation (STAR) is a treatment option for recurrent ventricular tachycardia/fibrillation (VT/VF) in patients with structural heart disease (SHD). The current and future role of STAR as viewed by Cardiologists is unknown. Objective To assess the current role, barriers to application and expected future role of STAR. Methods An online survey consisting of 20 questions on baseline demographics, awareness/access, current use, and the future role of STAR was conducted. Results 129 international participants completed the survey (mean age 43±11 years, 25 (16.4%) female). Ninety-one (59.9%) participants were electrophysiologists. Nine participants (7%) were unaware of STAR as a therapeutic option. Sixty-four (49.6%) had access to STAR while 62 (48.1%) had treated/referred a patient for treatment. Common primary indications for STAR were recurrent VT/VF in SHD (45%), recurrent VT/VF without SHD (7.8%) or premature ventricular contraction (PVC, 3.9%). Reported main advantages of STAR were efficacy in the treatment of arrhythmias not amenable to conventional treatment (49%) and noninvasive treatment approach with overall low expected acute and short-term procedural risk (23%). Most respondents have foreseen a future clinical role of STAR in the treatment of VT/VF with or without underlying SHD (72% and 75%, respectively), although only a minority expected a first-line indication for it (7% and 5%, respectively). Conclusions STAR as a novel treatment option of recurrent VT appears to gain acceptance within the cardiology community. Further trials are critical to further define efficacy, patient populations, as well as the appropriate clinical use for the treatment of VT.